Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657612 | 1.00 | ALOX5 (0.31) | ALOX5ACHEBACE1POLBSMN1; SMN2 | |
| SCHEMBL5659091 | 0.88 | KDM4E (0.37) | POLBSMN1; SMN2 | |
| SCHEMBL5659089 | 0.88 | KDM4E (0.37) | POLBSMN1; SMN2 | |
| SCHEMBL5657384 | 0.85 | MEN1 (0.32) | — | |
| SCHEMBL5657381 | 0.85 | MEN1 (0.32) | — | |
| SCHEMBL5656652 | 0.85 | KDM4E (0.32) | SMN1; SMN2 | |
| SCHEMBL5656650 | 0.85 | KDM4E (0.32) | SMN1; SMN2 | |
| SCHEMBL5658290 | 0.84 | SMN1; SMN2 (0.36) | POLBSMN1; SMN2 | |
| SCHEMBL5658293 | 0.84 | SMN1; SMN2 (0.36) | POLBSMN1; SMN2 | |
| SCHEMBL5661058 | 0.84 | ACHE (0.43) | ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030130-B2 | Benzofuran derivatives and their use as antibacterial agents | ARPIDA AG (CH) | 2006-04-18 | — | — | US | disclosed |
| EP-1307445-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | EVOLVA SA (CH) | 2004-02-19 | — | — | US | disclosed |
| EP-1307445-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Arpida AG, (CH) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010157-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | SBDS, BPTF, DCXR | ALOX5 1459/4885ACHE 3638/4885BACE1 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.